India’s First Preventive SMA Treatment Rolled Out in Kerala

Thiruvananthapuram: In a first-of-its-kind move in India, Kerala has begun pre-symptomatic treatment for Spinal Muscular Atrophy (SMA), a rare genetic disorder. The treatment was given to a newborn in Thiruvananthapuram within days of birth, marking a significant step forward in early intervention for rare diseases in the country.

The infant, born to a couple with a known history of SMA, received the medication Risdiplam — an expensive drug provided free of cost through government support. SMA is a genetic condition that affects muscle strength and movement. If left untreated, it can lead to severe physical disabilities or even early death in children.

The treatment was arranged at the SAT Hospital in Thiruvananthapuram, following genetic counseling and risk assessment during pregnancy. A panel of experts monitored the baby's condition and followed established international protocols to ensure timely care.

When both parents are carriers of the SMA gene, there is a 50% chance that their child could be affected. Studies estimate that SMA affects about one in every 7,000 births in India. The case is part of Kerala’s broader efforts under the CARE project launched in 2024, aimed at providing free treatment and long-term support to children with rare diseases. So far, more than 100 children have received help through the scheme, including access to costly medicines and corrective surgeries.

Health officials say the successful administration of pre-symptomatic treatment could pave the way for early genetic screening and intervention programs in other parts of the country.